Vanguard Group Inc. Decreases Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Vanguard Group Inc. lowered its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 0.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,973,141 shares of the medical equipment provider’s stock after selling 15,908 shares during the quarter. Vanguard Group Inc. owned approximately 10.18% of Lantheus worth $432,335,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Tucker Asset Management LLC lifted its stake in Lantheus by 239.0% in the third quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 282 shares during the last quarter. Principal Securities Inc. purchased a new stake in shares of Lantheus during the 4th quarter worth approximately $28,000. Covestor Ltd lifted its position in shares of Lantheus by 62.7% during the 3rd quarter. Covestor Ltd now owns 527 shares of the medical equipment provider’s stock worth $37,000 after buying an additional 203 shares during the last quarter. Parkside Financial Bank & Trust lifted its position in shares of Lantheus by 36.6% during the 3rd quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider’s stock worth $40,000 after buying an additional 156 shares during the last quarter. Finally, First Horizon Advisors Inc. lifted its position in shares of Lantheus by 103.9% during the 4th quarter. First Horizon Advisors Inc. now owns 932 shares of the medical equipment provider’s stock worth $58,000 after buying an additional 475 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Truist Financial boosted their price objective on shares of Lantheus from $82.00 to $96.00 and gave the stock a “buy” rating in a research report on Friday, May 3rd. B. Riley boosted their price objective on shares of Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research report on Thursday, April 18th. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a report on Friday, May 3rd. Finally, Mizuho lifted their target price on shares of Lantheus from $90.00 to $100.00 and gave the company a “buy” rating in a report on Friday, May 3rd. Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Lantheus has an average rating of “Moderate Buy” and a consensus target price of $99.17.

Insider Buying and Selling at Lantheus

In other Lantheus news, CAO Andrea Sabens sold 341 shares of the business’s stock in a transaction on Monday, May 13th. The shares were sold at an average price of $76.89, for a total value of $26,219.49. Following the transaction, the chief accounting officer now directly owns 62,898 shares of the company’s stock, valued at approximately $4,836,227.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other Lantheus news, Director Heinz Christoph Maeusli sold 18,373 shares of the business’s stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $79.19, for a total transaction of $1,454,957.87. Following the sale, the director now directly owns 23,340 shares in the company, valued at approximately $1,848,294.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Andrea Sabens sold 341 shares of the business’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $76.89, for a total transaction of $26,219.49. Following the sale, the chief accounting officer now owns 62,898 shares in the company, valued at $4,836,227.22. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,269 shares of company stock valued at $2,557,300. 1.50% of the stock is owned by company insiders.

Lantheus Stock Performance

Shares of Lantheus stock opened at $78.52 on Thursday. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.84 and a quick ratio of 4.55. The stock has a market capitalization of $5.44 billion, a price-to-earnings ratio of 11.99 and a beta of 0.56. The firm’s fifty day simple moving average is $76.70 and its 200-day simple moving average is $65.90. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $91.81.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.51 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.11. The company had revenue of $369.98 million for the quarter, compared to analysts’ expectations of $349.46 million. Lantheus had a net margin of 33.72% and a return on equity of 54.10%. As a group, equities analysts forecast that Lantheus Holdings, Inc. will post 6.51 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.